関連する実験動画
Updated: May 11, 2026

06:48
Breakfast Habits among Schoolchildren in the City of Uruguaiana, Brazil
Published on: July 29, 2020
処方箋なしの減量剤の使用:多州調査の結果
H M Blanck1, L K Khan, M K Serdula
1Division of Nutrition and Physical Activity, 4770 Buford Hwy NE, MS K-26, Atlanta, GA 30341-3717, USA. Hblanck@cdc.gov
JAMA
|August 31, 2001
まとめ
大人の7%が処方箋なしで減量剤を使用しており,肥満の若い女性の方が多い. また,処方されたダイエット錠剤も多く使用しており,臨床医の意識の必要性を強調しています.
科学分野:
- 公衆衛生は公衆衛生である.
- ダイエットサプリメント 栄養補助食品
- 肥満に関する研究
背景:
- 減量のためのライフスタイルの変化は,ダイエット製品の魅力を高め,挑戦的です.
- フェニルプロポナラミン (PPA) やエフェドラなどの非処方体重減少剤に安全性に関する懸念があります.
研究 の 目的:
- 処方箋なしの減量剤の使用率を判断するために.
- 人口統計,処方箋ダイエットピルの使用,糖尿病の状態,ライフスタイルによる使用パターンを分析します.
主な方法:
- 1998年の行動リスク因子監視システム調査のデータを活用した.
- サンプルには,米国の5つの州で14679人の非制度化された成人が含まれていました.
主要な成果:
- 総計,非処方体重減少剤の使用率は7%で,2%がPPA,1%がエフェドラを使用していました.
- 肥満の若い女性は (28.4%) 最も高い使用率を示しました.
- 使用者は,非使用者と比較して,身体的にアクティブになる可能性が高くなりました.
結論:
- 非処方薬の減量剤の使用は,肥満率の増加とともに増加すると予想されています.
- 医療提供者は,処方箋と非処方箋の両方の減量補助剤の患者の使用について尋ねるべきです.
関連する概念動画
Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

